Silver Standard Resources Inc

9.56

0.0000

成交量：- -

成交额：- -

市值：11.42亿

市盈率：16.48

高：9.56

开：9.56

低：9.56

收：9.56

52周最高：15.84

52周最低：7.70

股本：1.19亿

流通股本：8,050.00万

量比：- -

换手率：- -

股息：- -

股息率：- -

每股收益(TTM):0.5800

净资产收益率：--

总资产收益率：--

市净率：1.24

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

概念

没有相关数据

资金流向

资金流入：

资金流出：

新闻资讯

绿叶制药：若欣林治疗广泛性焦虑障碍的中国Ⅲ期临床试验完成所有患者入组

格隆汇

·

2025/08/18

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎国际,美股交易,港股交易,交易美股,股票信息,股价,美股行情,美股打新,港股打新,IPO打新,购买美股,全球投资","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/SSRI"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"SSRI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SSRI\",,,,,undefined,":{"symbol":"SSRI","market":"US","secType":"STK","nameCN":"Silver Standard Resources Inc","latestPrice":9.56,"timestamp":1502136000000,"preClose":9.56,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":80500000,"shares":119488000,"eps":0.58,"marketStatus":"退市","change":0,"latestTime":"08-07 16:00:00 EDT","open":9.56,"high":9.56,"low":9.56,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.58,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":9.56,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SSRI\",,,,,undefined,":{"symbol":"SSRI","floatShares":80500000,"roa":"--","roe":"--","lyrEps":0,"shares":119488000,"dividePrice":0,"high":9.56,"amplitude":0,"preClose":9.56,"low":9.56,"week52Low":7.7,"pbRate":"1.24","week52High":15.84,"institutionHeld":0.5011,"latestPrice":9.56,"eps":0.58,"divideRate":0,"volume":0,"delay":0,"ttmEps":0.58,"open":9.56},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SSRI\",params:#limit:5,,,undefined,":[{"date":"2017-08-03","symbol":"SSRI","newSymbol":"SSRM","type":"symbolChange","dateTimestamp":1501732800000},{"market":"US","date":"2017-05-03","symbol":"SSRI","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盘后","type":"earning","dateTimestamp":1493784000000,"reportTimeType":"post","actualEps":0.17},{"market":"US","date":"2017-02-23","symbol":"SSRI","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盘后","type":"earning","dateTimestamp":1487826000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2016-11-08","symbol":"SSRI","fiscalQuarterEnding":null,"expectedEps":0.18,"name":null,"time":"盘后","type":"earning","dateTimestamp":1478581200000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2016-08-10","symbol":"SSRI","fiscalQuarterEnding":null,"expectedEps":0.14,"name":null,"time":"盘后","type":"earning","dateTimestamp":1470801600000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SSRI\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SSRI\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SSRI\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2560079979","title":"绿叶制药：若欣林治疗广泛性焦虑障碍的中国Ⅲ期临床试验完成所有患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2560079979","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560079979?lang=zh_cn&edition=fundamental","pubTime":"2025-08-18 12:34","pubTimestamp":1755491640,"startTime":"0","endTime":"0","summary":"格隆汇8月18日丨绿叶制药宣布，集团自主研发的1类创新药若欣林用于治疗广泛性焦虑障碍的Ⅲ期临床试验已完成所有患者入组。该项Ⅲ期临床试验为一项多中心、随机、双盲、安慰剂对照的研究，以评估若欣林治疗广泛性焦虑障碍的安全性和有效性。若欣林是中国首个自主研发并拥有自主知识产权，用于治疗抑郁症的化药1类创新药，自2022年在中国获批上市以来，其治疗抑郁症的疗效和安全性不断获得临床认可。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250818123607974e6101&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250818123607974e6101&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4092","IE0002270589.USD","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","NE","SSRI","IE00B19Z3581.USD"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":1,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/SSRI\",params:#limit:6,delay:false,,,undefined,":[]}}